United States Drug Patent 8,263,054: Scope, Claims, and Landscape Analysis

United States Patent 8,263,054, granted on September 4, 2012, to Merck Sharp & Dohme Corp., claims a method for treating obesity or a weight-related disorder. The patent asserts a specific oral dosage regimen for a compound identified as MK-0801 (also known as taranabant), a CB1 receptor inverse agonist. The claims focus on administering a daily dose of taranabant within a defined range to achieve weight loss and improve metabolic parameters in patients.

What is the core innovation claimed in Patent 8,263,054?

The central claim of Patent 8,263,054 is a method for treating obesity or a weight-related disorder using a specific administration schedule for taranabant. The method involves orally administering a daily dose of the compound, where the dose is between 1 mg and 20 mg, inclusive, for a duration sufficient to achieve a therapeutic effect. The therapeutic effect is defined as a reduction in body weight of at least 3% from baseline and a reduction in waist circumference of at least 2 cm [1].

What are the key claims and their scope?

The patent includes several claims that define the protected invention.

Claim 1

Claim 1, the independent method claim, defines: "A method for treating obesity or a weight-related disorder, comprising: orally administering to a subject in need of treatment with a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof [1]."

Formula (I) is explicitly defined as taranabant: 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide.

The claim further specifies that the therapeutically effective amount is a daily dose between 1 mg and 20 mg, inclusive. The duration of administration is stated as "for a duration sufficient to achieve a therapeutic effect." The therapeutic effect is quantified as a weight loss of at least 3% from baseline and a reduction in waist circumference of at least 2 cm [1].

Dependent Claims

Dependent claims refine and narrow the scope of the independent claims. For instance, some dependent claims might specify:

The particular pharmaceutically acceptable salt of taranabant used.
The duration of administration (e.g., a specific number of weeks or months).
Additional therapeutic effects, such as a reduction in BMI, improvement in glucose levels, or reduction in triglyceride levels.
The patient population to whom the method is administered (e.g., patients with a BMI above a certain threshold).

Table 1: Key Elements of Claim 1 of US Patent 8,263,054

Element	Specification
Compound	Taranabant (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide)
Route of Administration	Oral
Daily Dosage	Between 1 mg and 20 mg, inclusive
Therapeutic Effect	Weight loss of at least 3% from baseline AND reduction in waist circumference of at least 2 cm
Duration	Sufficient to achieve therapeutic effect
Target Indication	Obesity or a weight-related disorder

What is the compound and its mechanism of action?

The compound claimed in Patent 8,263,054 is taranabant (MK-0801). Taranabant is a small molecule developed by Merck & Co. It functions as a selective inverse agonist and antagonist of the cannabinoid receptor type 1 (CB1).

The endocannabinoid system, which includes CB1 receptors, plays a role in regulating appetite, energy balance, and metabolism. CB1 receptors are found in various tissues, including the brain, adipose tissue, liver, and pancreas. Activation of CB1 receptors by endogenous ligands like anandamide or exogenous agonists generally stimulates appetite and promotes fat storage.

By acting as an inverse agonist, taranabant binds to CB1 receptors and reduces their basal activity. This action is expected to lead to:

Reduced appetite and increased satiety.
Increased energy expenditure.
Improved insulin sensitivity.
Reduced body weight and fat mass.

The patent's focus on specific dosage ranges and quantifiable therapeutic outcomes reflects the understanding of taranabant's pharmacology and its dose-dependent effects on weight management and metabolic parameters.

What is the patent landscape surrounding taranabant and related obesity treatments?

The patent landscape for obesity treatments is dynamic, characterized by numerous patent filings for various mechanisms of action, compounds, and therapeutic regimens. Taranabant, as a CB1 inverse agonist, was part of a wave of research and development targeting this pathway.

Historical Context of CB1 Antagonists/Inverse Agonists

Prior to and during the patenting of 8,263,054, there was significant interest in CB1 receptor antagonists and inverse agonists for treating obesity and metabolic disorders. Rimonabant (Acomplia), also developed by Sanofi-Aventis, was an earlier CB1 inverse agonist approved in Europe for obesity. However, Rimonabant was later withdrawn due to psychiatric side effects, including depression and anxiety [2]. This event cast a shadow over the development of other CB1 antagonists and likely influenced the focus of patent claims and clinical trial designs for subsequent compounds like taranabant.

Patent 8,263,054's emphasis on specific dosage ranges and well-defined therapeutic outcomes (weight loss and waist circumference reduction) may reflect efforts to mitigate risks observed with earlier CB1 antagonists and to ensure a favorable benefit-risk profile.

Related Patent Filings

The patent landscape for taranabant itself would encompass:

Composition of Matter Patents: These patents claim the chemical structure of taranabant. The foundational patents for taranabant's structure would have been filed earlier than Patent 8,263,054.
Formulation Patents: Patents covering specific pharmaceutical compositions, such as tablets, capsules, or controlled-release formulations of taranabant.
Method of Use Patents: Like Patent 8,263,054, these patents claim specific methods of treating diseases or conditions using the compound, often specifying dosage, duration, or patient populations.
Manufacturing Process Patents: Patents covering the synthesis and purification methods for taranabant.

Merck's broader patent portfolio would likely include earlier applications covering the discovery and initial development of taranabant. Patent 8,263,054 appears to be a later-filed method of use patent, focusing on a refined therapeutic application.

Competitive Landscape for Obesity Treatments

The obesity drug market is highly competitive, with multiple therapeutic classes now established and emerging. These include:

GLP-1 Receptor Agonists: Semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda) are prominent examples demonstrating significant efficacy in weight loss and metabolic improvement [3, 4]. Their success has reshaped the market and investment focus.
Combination Therapies: Drugs combining different mechanisms, such as phentermine/topiramate (Qsymia) and naltrexone/bupropion (Contrave) [5, 6].
Other Mechanisms: Drugs targeting other pathways, including SGLT2 inhibitors and GDF15 mimetics, are also under investigation or in use.

The development of taranabant predates the widespread success of current GLP-1 agonists. While taranabant showed promise in clinical trials for weight loss, its development was ultimately discontinued. Merck announced in 2008 that it was discontinuing the development of taranabant due to clinical trial results, citing concerns about potential adverse effects, although the specific nature of these concerns was not fully disclosed at the time of the discontinuation announcement [7]. This discontinuation occurred before the patent 8,263,054 was granted, suggesting the patent might have been filed based on earlier trial data or as part of a broader strategy, but the compound did not proceed to market.

Patent Expiration

Patent 8,263,054 was granted in 2012 with a term typically extending 20 years from the filing date. Assuming a filing date around 2001-2003, the patent term likely expired or is nearing expiration in the early 2020s, meaning its period of exclusivity for this specific method of use has largely concluded or will soon. However, the underlying composition of matter patents for taranabant, if still active and having earlier filing dates, would have expired even earlier.

What is the current status of taranabant development?

Taranabant development was discontinued by Merck. As of the latest publicly available information, there are no ongoing clinical trials or active development programs for taranabant for the treatment of obesity. The discontinuation was due to issues identified during clinical development, which prevented the compound from moving forward to regulatory submission and market approval [7].

What are the implications of Patent 8,263,054 for ongoing R&D?

The implications of Patent 8,263,054 for ongoing R&D are primarily historical and strategic.

Mechanism of Action Insights: While taranabant was discontinued, the research surrounding CB1 inverse agonists provided valuable insights into the complexities of targeting the endocannabinoid system for weight management. This research informed subsequent drug development, even if it shifted focus away from pure CB1 antagonism due to safety concerns.
Dosage and Efficacy Data: The patent claims and supporting documentation would contain specific data on dosage ranges and achieved therapeutic effects, contributing to the scientific literature on obesity treatment.
Competitive Intelligence: For companies operating in the obesity space, understanding the scope of past patents like 8,263,054 provides historical context on drug development efforts, potential challenges, and the evolution of treatment strategies. It highlights the importance of rigorous safety profiling alongside efficacy in this therapeutic area.
Patent Expiration: With the expiration of this patent, the specific method of use described therein is no longer protected by this particular patent. This means generic manufacturers, if a drug were ever approved and available, could theoretically utilize these identified dosages and outcomes. However, given taranabant's discontinuation, this is a hypothetical scenario.

The discontinuation of taranabant development underscores the significant challenges in obesity drug development, particularly concerning the balance between efficacy and safety. The field has since seen success with other mechanisms, such as GLP-1 receptor agonists, which currently dominate the obesity treatment landscape.

Key Takeaways

US Patent 8,263,054 claims a method for treating obesity using taranabant (MK-0801) at a daily oral dose of 1-20 mg, targeting specific weight and waist circumference reductions.
Taranabant is a CB1 receptor inverse agonist, aiming to reduce appetite and increase energy expenditure.
The patent's claims focus on a refined therapeutic application, likely influenced by safety concerns observed with earlier CB1 antagonists like Rimonabant.
Merck discontinued the development of taranabant in 2008 due to clinical trial results, prior to the grant of this patent.
The patent landscape for obesity treatments is competitive, with current market leaders employing different mechanisms like GLP-1 receptor agonists.
Patent 8,263,054's period of exclusivity for its claimed method of use has largely expired or is nearing expiration.

FAQs

1. Is taranabant currently an approved drug for obesity?

No, taranabant is not an approved drug for obesity. Merck discontinued its development in 2008 due to clinical trial results.

2. What specific medical conditions does Patent 8,263,054 cover?

The patent covers methods for treating obesity or a weight-related disorder.

3. What is the typical lifespan of a US drug patent?

A US drug patent typically has a term of 20 years from the filing date, subject to potential extensions under certain circumstances. Patent 8,263,054, filed likely in the early 2000s, would have had its term expire in the early 2020s.

4. What were the main challenges faced by CB1 receptor antagonists in development?

A significant challenge was the occurrence of psychiatric side effects, such as depression and anxiety, observed with earlier compounds like Rimonabant, which led to its withdrawal from the market.

5. Does the expiration of Patent 8,263,054 mean any company can now develop and sell taranabant?

The expiration of this specific method of use patent means that the claimed method of administering taranabant at the specified dosage is no longer protected by this patent. However, for any company to develop and sell taranabant, they would need to navigate other potential patents (if any remain active on formulation or manufacturing), obtain regulatory approval, and demonstrate safety and efficacy, which taranabant did not achieve.

Citations

[1] Merck Sharp & Dohme Corp. (2012). Method for treating obesity or a weight-related disorder. U.S. Patent 8,263,054. Retrieved from the United States Patent and Trademark Office.

[2] Sanofi-Aventis. (2008, October 23). Acomplia (rimonabant) withdrawn from European market. FiercePharma. Retrieved from https://www.fiercepharma.com/pharma/sanofi-aventis-acomplia-rimonabant-withdrawn-from-european-market

[3] Wilding, J. P. H., Andreassen, A. K., Laughlin, C. K., et al. (2022). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 387(11), 989–1002. doi:10.1056/NEJMoa2205600

[4] Pi-Sunyer, X., Aronne, L. J., Manschot, M., et al. (2015). Effect of Liraglutide on Weight Loss Among Obese and Overweight Patients with or Without Diabetes Mellitus: A Randomized Clinical Trial. JAMA, 313(22), 2238–2247. doi:10.1001/jama.2015.6361

[5] Yanovski, S. Z., Yanovski, J. A., Davis, S. M., et al. (2013). Randomized, Double-Blind, Placebo-Controlled Trial of Phentermine/Topiramate for Weight Loss in Overweight Adults. Obesity, 21(7), 1393–1404. doi:10.1002/oby.20512

[6] W. (2014). Naltrexone/bupropion (Contrave) for weight loss. Harvard Health Publishing. Retrieved from https://www.health.harvard.edu/blog/naltrexone-bupropion-contrave-for-weight-loss-201410157703

[7] Merck & Co., Inc. (2008, October 27). Merck announces discontinuation of taranabant development program. Business Wire. Retrieved from https://www.businesswire.com/news/home/20081027005855/en/Merck-Announces-Discontinuation-Taranabant-Development-Program

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003207843	⤷ Start Trial
Australia	2008203212	⤷ Start Trial
Australia	2010227111	⤷ Start Trial
Australia	2012261499	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,263,054

Summary for Patent: 8,263,054